| 000 | 04651cam a22004937a 4500 | ||
|---|---|---|---|
| 999 |
_c10510 _d10510 |
||
| 001 | 17591741 | ||
| 003 | EG-NcFUE | ||
| 005 | 20200930112454.0 | ||
| 008 | 130115s2012 enka b 001 0 eng | ||
| 010 | _a 2012472658 | ||
| 016 | 7 |
_a101580436 _2DNLM |
|
| 020 | _a9781848166288 | ||
| 020 | _a1848166281 | ||
| 035 | _a(OCoLC)ocn776670289 | ||
| 040 |
_aNLM _beng _cNLM _dCAI _dCDX _dYDXCP _dE7B _dBTCTA _dBWX _dDLC |
||
| 042 |
_anlmcopyc _alccopycat |
||
| 050 | 0 | 0 |
_aRS201.A56 _bA58 2012 |
| 060 | 0 | 0 | _a2012 C-123 |
| 060 | 1 | 0 | _aQW 575 |
| 082 | 0 | 4 |
_a615.37 _222 _bA |
| 245 | 0 | 0 |
_aAntibody drug discovery / _cClive R. Wood, editor. |
| 264 | 1 |
_aLondon : _bImperial College Press, _c[2012]. |
|
| 264 | 4 | _c©2012 | |
| 300 |
_axv, 473 pages : _billustrations (some color) ; _c24 cm |
||
| 336 |
_2rdacontent _atext |
||
| 337 |
_2rdamedia _aunmediated |
||
| 338 |
_2rdacarrier _avolume |
||
| 490 | 1 |
_aMolecular medicine and medicinal chemistry ; _vv. 4 |
|
| 500 | _apharmacy bookfair2016 | ||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aContributors -- Foreword John McCafferty -- Preface Clive R.Wood -- Chapter 1 Humanization of Antibodies Olivier Léger and José W. Saldanha -- 1.1 Introduction -- 1.1.1 First step: chimerization -- 1.2 CDR Grafting: Standard Technology -- 1.2.1 Choice of CDR region to graft -- 1.2.2 Choice of human framework acceptor regions -- 1.2.2.1 Fixed frameworks -- 1.2.2.2 Best fit -- 1.2.2.3 Consensus -- 1.2.2.4 Germline -- 1.2.3 Backmutations -- 1.3 Affinity versus Stability -- 1.4 Alternative Approaches -- 1.4.1 Veneering or resurfacing -- 1.4.2 Grafting of abbreviated CDRs containing specificity-determining residues 1.4.3 Superhumanization1.4.4 Human string content optimization -- 1.4.5 Framework shuffling and human framework adaptation -- 1.4.6 Combinatorial library approaches -- 1.4.6.1 Guided selection -- 1.4.6.2 Framework libraries -- 1.4.7 HumaneeringTM technology -- 1.5 Concluding Remarks -- References -- Chapter 2 Selection and Screening of Antibody Phage Display Libraries David R. Buckler, Darren Schofield, Daniel J. Sexton, David Lowe and Tristan J. Vaughan -- 2.1 Introduction -- 2.2 Antibody Gene Rearrangement and Variable Region Sequence Diversity 2.2.1 Antibody architecture and germline gene segment recombination2.2.2 Variable region sequence diversity and structure guiding library design -- 2.2.3 Amplification of variable region sequence repertoires -- 2.2.4 Antibody sequence databases -- 2.3 Antibody Display Libraries in Ff Bacteriophage -- 2.3.1 Phage biology and early use as a display system -- 2.3.2 Variation of display format and control of display level -- 2.3.2.1 Coat protein display position -- 2.3.2.2 Display format, scFv vs. Fab -- 2.3.2.3 Signal peptide and vector design -- 2.3.2.4 Control of functional display level and valency 2.3.2.5 Maximizing library size2.3.2.6 Assessment of diversity -- 2.3.3 Representative large non-immune libraries -- 2.4 Library Selection -- 2.4.1 Antigen immobilization -- 2.4.2 Overview of phage display selection -- 2.4.3 Advantages and successes of phage display -- 2.4.3.1 Species cross-reactivity -- 2.4.3.2 Homolog binders -- 2.4.3.3 Rare epitopes -- 2.4.3.4 Exquisite specificity -- 2.4.3.5 Cell surface antigens -- 2.4.3.6 Toxins -- 2.4.3.7 High-throughput generation of reagents for proteomics -- 2.4.4 Advances in selection technology -- 2.5 Library Screening -- 2.5.1 Primary screening methods 2.5.2 Secondary screening methods2.5.3 High-throughput antibody purification -- 2.6 Future Applications of Antibody Phage Display -- 2.6.1 Antibody phage display in the proteomics arena -- 2.6.2 Quality protein reagents -- 2.6.3 Affinity maturation of antibody outputs -- 2.6.4 Antibody format and production -- 2.7 Conclusions -- References -- Chapter 3 Affinity Maturation Approaches for Antibody Lead Optimization David Lowe, Trevor Wilkinson and Tristan J. Vaughan -- 3.1 Introduction -- 3.2 Measuring the Affinity of Antibody-Antigen Complexes -- 3.2.1 Improving antibody affinity and potency | |
| 650 | 0 | _aAntibody-drug conjugates. | |
| 650 | 0 | _aDrug development. | |
| 650 | 0 | _aImmunoglobulins. | |
| 650 | 1 | 2 | _aAntibodies. |
| 650 | 2 | 2 | _aDrug Discovery. |
| 650 | 2 | 2 | _aImmunoglobulins. |
| 700 | 1 |
_aWood, Clive. _eauthor. |
|
| 830 | 0 |
_aMolecular medicine and medicinal chemistry ; _vv. 4. |
|
| 856 |
_3Abstract _uhttp://repository.fue.edu.eg/xmlui/handle/123456789/1826 |
||
| 906 |
_a7 _bcbc _ccopycat _d2 _encip _f20 _gy-gencatlg |
||
| 942 |
_2ddc _cBK |
||